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Abstract
Youth with inflammatory bowel disease (IBD) often experience psychological difficulties, such as anxiety and depression. 
This randomized controlled study tested whether a 3-month disease-specific cognitive behavioral therapy (CBT) in addition to 
standard medical care versus standard medical care only was effective in improving these youth’s psychological outcomes. As 
this study was aimed at prevention, we included 70 youth (10–25 years) with IBD and symptoms of subclinical anxiety and/
or depression, and measured psychological outcomes at 6- and 12-month follow-up. In general, participants in both groups 
showed improvements in anxiety, depression, health-related quality of life, social functioning, coping, and illness perceptions, 
sustained until 12 months follow-up. Overall, we found no differences between those receiving additional CBT and those 
receiving standard medical care only. We assume that this can be explained by the perceived low burden (both somatically 
and psychologically) or heightened awareness of psychological difficulties and IBD. ClinicalTrials.gov NCT02265588.
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Inflammatory bowel disease (IBD) is a chronic inflammatory 
disorder of the gastrointestinal tract characterized by periods 
of active inflammation (with increased clinical symptoms) 
followed by periods of clinical remission. The two main 
types of IBD are Crohn’s disease (CD) and ulcerative coli-
tis (UC). Symptoms are abdominal pain, bloody diarrhea, 
fatigue, fever, and weight loss (Griffiths, 2004; Rose, Dha-
wan, & Saeed, 2015). Pediatric patients may also show ano-
rexia/loss of appetite, malnutrition, and delayed growth and 
puberty onset—especially those with CD (Adamiak et al., 
2013; Sauer & Kugathasan, 2009).
Adolescents and young adults (hereafter referred to as 
youth) with IBD may experience various psychological 
problems related to the disease and its treatment. Firstly, 
they are at risk for anxiety and depression (Brooks et al., 
2016; Greenley et al., 2010). More specifically, a large 
cohort study found that these youth have a higher risk for 
anxiety or depressive disorders (Loftus Jr et al., 2011). 
Secondly, they are at risk for a lower health-related quality 
of life (HRQOL) compared to that of healthy peers (Ross, 
Strachan, Russell, & Wilson, 2011), likely on account of 
more maladaptive avoidant coping (Van der Zaag-Loonen, 
Grootenhuis, Last, & Derkx, 2004; McCombie, Mulder, & 
Gearry, 2013). In addition, negative illness perceptions (i.e., 
negative cognitions on for example the consequences of the 
 * Elisabeth M. W. J. Utens 
 e.utens@erasmusmc.nl
1 Department of Child and Adolescent Psychiatry/Psychology, 
Erasmus MC-Sophia Children’s Hospital, P.O. Box 2060, 
3000 CB Rotterdam, The Netherlands
2 Department of Pediatric Gastroenterology, Erasmus 
MC-Sophia Children’s Hospital, Rotterdam, The Netherlands
3 Department of Psychiatry, University of Pittsburgh, 
Pittsburgh, PA, USA
4 Department of Pediatrics, Maasstad Hospital, Rotterdam, 
The Netherlands
5 Department of Gastroenterology, Maasstad Hospital, 
Rotterdam, The Netherlands
6 Research Institute of Child Development and Education, 
University of Amsterdam, Amsterdam, The Netherlands
7 Academic Center for Child Psychiatry 
the Bascule/Department of Child and Adolescent Psychiatry, 
Academic Medical Center, Amsterdam, The Netherlands
491Journal of Clinical Psychology in Medical Settings (2020) 27:490–506 
1 3
disease or personal control) are associated with more nega-
tive outcomes in these youth (Knowles, Wilson, Connell, 
& Kamm, 2011; Rochelle & Fidler, 2013). Thirdly, youth 
with IBD also experience sleep problems (Manhart, Hell-
mann, Hamelmann, & Schlarb, 2016), related to anxiety, 
and depression (Pirinen, Kolho, Ashorn, & Aronen, 2014). 
Lastly, a study found that the social functioning of youth 
with IBD was lower than that of healthy controls (Greenley 
et al., 2010). In conclusion, youth with IBD are likely to 
experience psychological problems as described above, and 
the interrelationships between these problems make both 
somatical and psychological treatment of these youth even 
more complex.
Importantly, psychological problems of youth with IBD 
can influence their medical outcomes, creating a vicious 
circle of problems (e.g., Mikocka-Walus, Pittet, Rossel, von 
Kanel, & Swiss IBD Cohort Study Group, 2016a; Sweeney 
et al., 2018; Van Tilburg et al., 2017). A reciprocal rela-
tionship between these psychological problems and clini-
cal symptoms of gut inflammation seems to exist (Gracie, 
Guthrie, Hamlin, & Ford, 2018). It has been hypothesized 
that psychological interventions may positively influence the 
inflammatory disease course (Bonaz and Bernstein, 2013). 
Psychological treatment should be focused on decreasing 
anxiety and depression and addressing other psychological 
problems, such as coping or negative illness perceptions, 
and on improving HRQOL and daily functioning. A recent 
randomized controlled trial (RCT) of Levy et al. (2016) 
in pediatric patients with IBD tested the effect of a three-
session social learning and cognitive behavioral therapy 
(SLCBT) versus that of educational support (ES; focusing 
on the gastrointestinal system, food labels, and nutrition) on 
a large set of psychological outcomes. SLCBT outperformed 
educational support in improving IBD-related quality of life 
1 week after treatment and coping and school attendance 
over the course of 12 months, but had no beneficial effect on 
anxiety, depression, and functional disability. However, the 
study participants had not been selected on either somatic of 
psychological symptoms, and therefore, many of them did 
not have psychological problems. Mikocka-Walus, Andrews, 
& Bampton (2016b) have suggested that targeted psycho-
logical treatment may be more useful to tackle psychologi-
cal problems such as elevated anxiety and/or depression. 
Furthermore, Levy et al. (2016) used only three sessions, 
whereas in IBD it has been shown that a full 12-session 
protocol of disease-specific CBT improved depressive symp-
toms and HRQOL (Szigethy et al., 2014; Thompson et al., 
2012).
We performed a RCT named HAPPY-IBD and aimed to 
test the extent to which disease-specific CBT in youth with 
subclinical anxiety and depression is effective to decrease 
these psychological problems (anxiety and depression, but 
also the other above-mentioned psychological factors). A 
previous study found that CBT was effective in decreasing 
subclinical depression in youth with IBD (Szigethy et al., 
2007; Thompson et al., 2012). The ultimate objective of 
providing CBT specifically for these subclinical symptoms 
was to improve the disease course and to prevent the devel-
opment of clinical anxiety and depressive disorders. Thus, 
the study was aimed at secondary prevention. To cover 
the important life phase of transition from adolescence to 
adulthood, we included youth aged 10–25 years. In this life 
phase, IBD can affect the psychological development, such 
as becoming independent from parents, developing long-
term friendships, and forming an own (sexual) identity. 
For teenagers, important changes are starting secondary 
education, making new friends at a new school, becoming 
more independent from parents, and spending more time 
with peers. For late adolescents, these processes continue 
and graduating, experimenting with alcohol or drugs, find-
ing a (side) job and earning money, and forming an iden-
tity will happen well. Young adults face developmental 
challenges such as finding a job, leaving home, having 
long-lasting romantic relationships, and becoming finan-
cially independent (Arnett, 2010). A diagnosis of IBD can 
involve a sense of loss in, for example, body image, future 
plans, self-confidence, sense of control, and roles inside 
and outside the family context (Szigethy, McLafferty, & 
Goyal, 2011). These changes and challenges should be 
considered in the treatment of youth with IBD.
Earlier we have reported the results of the immediate 
post-treatment assessment of this RCT, 3 months after 
baseline: youth in both the CBT and the standard medical 
care group showed improvements in anxiety, depression, 
and HRQOL, to a similar level in each group (Stapersma 
et al., 2018). Considering that IBD has a fluctuating dis-
ease course, we re-assessed the psychological outcomes 
at 6 and 12 months. We expected that patients who had 
received CBT would be better able to deal with possible 
flares and be better equipped with skills to prevent wors-
ening of their subclinical psychological problems. Since 
CBT in general aims to improve anxiety and depression, 
these were chosen as primary outcomes. In addition, in 
the current study, we extended and innovated the range 
of our outcomes and also measured HRQOL, social func-
tioning, coping (Kendall et al., 2016), illness perceptions 
(Christensen, Frostholm, Ornbol, & Schroder, 2015), and 
sleep problems.
In summary, the present study aims to test the effective-
ness of a full disease-specific CBT protocol in addition to 
standard medical care, 6 and 12 months after the baseline 
assessment, to improve anxiety and depressive symptoms, 
and other psychological outcomes, in youth with IBD 
(10–25 years old) and subclinical symptoms of anxiety and 
depression, compared to standard medical care only. We 
hypothesized that patients who had received CBT would 
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have more sustained improvement on all psychological out-
comes than those in the standard medical care group.
Methods
For details of this RCT and the 3-month outcomes, see Van 
den Brink et al. (2016) and Stapersma et al. (2018). This 
study was a two-armed multi-center parallel group RCT, 
comparing a disease-specific CBT (Primary and Secondary 
Control Enhancement Training for Physical Illness; PAS-
CET-PI; Szigethy et al., 2007) in addition to standard medi-
cal care to standard medical care only (care-as-usual, CAU). 
The latter represented the current usual care for youth with 
IBD in the Netherlands, and was therefore chosen as con-
trol condition. Patients were consecutively recruited between 
October 2014 and October 2016 in two academic and four 
community hospitals in urban and rural regions. The trial 
design adhered to the CONSORT guidelines for non-phar-
macological treatments (Boutron et al., 2017). The research 
protocol was approved by the Medical Ethics Committee of 
the Erasmus MC (approval number NL49147.078.14) and 
confirmed by the ethics boards of all participating hospitals. 
The study was registered with ClinicalTrials.gov as study 
number NCT02265588.
Participants and Assessment Procedure
After patients and/or their parents had provided written 
informed consent, they were included in two steps. Youth 
from the age of 12 years provided informed consent them-
selves as well; the 10- and 11-year olds provided assent. 
Parents provided informed consent for youth up to 18 years. 
All participants received as an incentive a 25 EUR voucher.
Step 1 involved baseline screening of anxiety and depres-
sion symptoms, for which all consecutive youth (aged 
10–25 years) with a confirmed diagnosis of IBD (CD, UC, or 
inflammatory bowel disease unclassified; IBD-U) recruited 
in the above-mentioned period were eligible.
Step 2, the actual RCT, included only youth with sub-
clinical anxiety or depression established in step 1, as we 
aimed to examine whether the disease-specific CBT could 
prevent clinical anxiety and/or depression. For that matter, 
it is unethical to withhold treatment to patients with clinical 
anxiety and/or depression.
The presence of subclinical anxiety or depressive symp-
toms was defined as a score equal or above the cutoff of age-
appropriate questionnaires, but not meeting criteria for clini-
cal anxiety and depression (see below). Subclinical anxiety 
symptoms were measured with the Screen for Child Anxi-
ety-Related Emotional Disorders (SCARED; 10–20 years; 
cutoff ≥ 26 for boys and ≥ 30 for girls; Bodden, Bögels, & 
Muris, 2009) and the Hospital Anxiety and Depression 
Scale-Anxiety Scale (HADS-A; 21–25 years; cutoff ≥ 8; De 
Croon, Nieuwenhuijsen, Hugenholtz, & Van Dijk, 2005). 
Subclinical depressive symptoms were measured with the 
Child Depression Inventory (CDI; 10–17 years; cutoff ≥ 13; 
Timbremont, Braet, & Roelofs, 2008) and the Beck Depres-
sion Inventory-second edition (BDI-II; 18–25 years; cut-
off ≥ 14; Van der Does, 2002).
These youth were assumed to suffer from clinical anxi-
ety or depression if they met DSM-5 criteria for an anxiety 
or depressive disorder, as assessed with a psychiatric inter-
view (Anxiety Disorders Interview Schedule for Children; 
ADIS-C; Siebelink and Treffers, 2001), and if they scored 
equal to or above the clinical cutoff on age-specific severity 
rating scales: the Pediatric Anxiety Rating Scale (PARS; 
10–20 years; cutoff ≥ 18; Ginsburg, Keeton, Drazdowski, & 
Riddle, 2011) or the Hamilton Anxiety Rating Scale (HAM-
A; 21–25 years; cutoff ≥ 15; Hamilton, 1959; Matza, Mor-
lock, Sexton, Malley, & Feltner, 2010) for anxiety; the Child 
Depression Rating Scale Revised (CDRS-R; 10–12 years; 
cutoff ≥ 40; Poznanski et al., 1984); the Adolescent Depres-
sion Rating Scale (ADRS; 13–20 years; cutoff ≥ 20; Revah-
Levy, Birmaher, Gasquet, & Falissard, 2007); or the Ham-
ilton Depression Rating Scale (HAM-D; 21–25  years; 
cutoff ≥ 17; Hamilton, 1960; Zimmerman, Martinez, Young, 
Chelminski, & Dalrymple, 2013) for depression. All above-
mentioned cutoffs only served for inclusion of patients and 
not for analysis purposes.
Youth with clinical anxiety or depression were referred to 
mental health care. Youth with subclinical anxiety or depres-
sive symptoms (but not clinical anxiety or depression) were 
randomized at a ratio 1:1 to receive either PASCET-PI in 
addition to CAU or CAU only.
Randomization
An independent biostatistician provided a computer-gener-
ated blocked randomization list with randomly chosen block 
sizes (with a maximum of 6) and stratification by center 
using the blockrand package in the R software package, 
thereby providing numbered envelopes per center. Partici-
pants were enrolled by a single investigator (GB). The inter-
viewer (LS) and treating physicians had no access to the 
files in which the randomization result was described. We 
requested the youth and their parents not to reveal the trial 
arm assignment to the interviewer and treating physicians. 
Youth and parents received a link to web-based question-
naires, to be completed at home. They completed the same 
set of questionnaires at baseline (no longer than 2 weeks 
before the start of the PASCET-PI), and at the post-assess-
ments (3, 6, and 12 months after baseline). For both groups, 
assessments were performed at comparable time points (i.e., 
between 11 and 13 weeks, 25 and 27 weeks, and 51 and 
53 weeks after randomization).
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Intervention
The PASCET-PI is a disease-specific CBT protocol for youth 
with IBD (Szigethy et al., 2007), consisting of ten weekly 
individual sessions, delivered in 3 months. It was provided in 
a ‘blended format’: six sessions were face-to-face with a psy-
chologist (in the young person’s own hospital), four sessions 
by telephone. In addition, parents of youth ≤ 20 years were 
invited for three face-to-face family sessions. Booster ses-
sions were delivered by telephone 4, 5, and 6 months after 
baseline. The authorized Dutch translation of the PASCET-
PI was used, which has been established by the research 
team. Originally, the PASCET-PI is targeted at depression. 
For this study, the treatment content was adjusted to also 
target aspects of anxiety such as anxiety hierarchy, expo-
sure, cognitive restructuring, and to also target young adults 
(with more age-appropriate exercises and lay-out). A more 
detailed description is provided in Appendix 1, Table 3 or 
van den Brink et al. 2016. In short, sessions are focused on 
discussing, in an age-attuned manner, the illness narrative 
and the link between behavior and feelings, relaxation, dis-
cussing negative thoughts and cognitive restructuring, and 
on personalizing the taught skills. The therapists provided 
age-appropriate information and exercises. In this way, the 
protocol took into account the youth’s psychological, cogni-
tive, and social development.
The therapy was provided by licensed (healthcare/CBT) 
psychologists with ample experience working with youth, 
who had all been trained by the developer (ES) and received 
monthly supervision by EU (clinical psychologist/professor). 
Treatment integrity was ensured by supervision of the thera-
pists and by rating of audiotaped sessions. For details, see 
Stapersma et al. (2018). CAU consisted of regular medical 
consultations of 15–30 min with the (pediatric) gastroenter-
ologist and/or IBD nurse every 3 months, in which overall 
wellbeing, disease activity, and future diagnostic/treatment 
plans were discussed.
Outcome Measures (Online Questionnaires)
Demographic data were obtained from a semi-structured 
questionnaire (Utens, van Rijen, Erdman, & Verhulst, 2000). 
Socioeconomic status was based on parents’ occupational 
level or, for youth living on their own, the own occupational 
level. We classified socioeconomic status into low, middle, 
and high (Statistics Netherlands, 2010). Ethnicity was based 
on the mother’s country of birth or, if the mother was born 
in the Netherlands, the father’s country of birth (Statistics 
Netherlands, 2000). Disease characteristics were extracted 
from the electronic medical charts.
Symptoms of anxiety were assessed with the SCARED 
(for 10–20 years), and the anxiety scale of the HADS (for 
21–25  years). Both are self-report questionnaires. The 
SCARED has 69-items with 3 response categories (0–2, 
total score 0–138; Muris, Bodden, Hale, Birmaher, & Mayer, 
2011). The anxiety scale of the HADS has 7-items with 4 
response categories (0–3, total score 0–21; De Croon et al. 
2005). Internal consistency at baseline and the three follow-
up assessments was .86, .92, .94, and .94, respectively, for 
the SCARED, and .54, .77, .81, .80, respectively, for the 
HADS-A. Clinical anxiety was established from a psychiat-
ric interview and severity rating scales (as described above 
in the assessment procedure).
Symptoms of depression were assessed using the CDI (for 
10–17 years) and the BDI-II (for 18–25 years) self-report 
symptoms scales. The CDI has 27-items with 3 response 
categories (0–2, total score 0–54; Timbremont et al., 2008). 
The BDI-II has 21-items with 4 response categories (0–3, 
total score 0–63; Van der Does, 2002). Internal consistency 
at baseline and the three follow-up assessments was .70, .77, 
.79, and .81, respectively, for the CDI, and .54, .83, .81, and 
.84, respectively, for the BDI-II. Clinical depression was 
established from a psychiatric interview and severity rating 
scales (as described above in the assessment procedure).
Health-related quality of life (including social func-
tioning) was assessed with the self-report questionnaires 
IMPACT-III (10–20 years) and the Inflammatory Bowel Dis-
ease Questionnaire (IBDQ; 21–25 years). The IMPACT-III 
has 35 items, scored 1–5 (total score 35–175; Otley et al., 
2002). The IBDQ contains 32 items, scored 1–5 (total 
score 32–160; De Boer, Wijker, Bartelsman, & de Haes, 
1995). For both instruments, a higher score indicates bet-
ter HRQOL. We included in the analyses the total scores 
and the individual subscale scores for social functioning of 
both instruments. For the total score, internal consistency at 
baseline and the three follow-up assessments was .71, .92, 
.90, and .90, respectively, for the IMPACT-III, and .71, .92, 
.85, and .88, respectively, for the IBDQ. For the social func-
tioning subscale score, internal consistency at baseline and 
the three follow-up assessments was .67, .54, .59, and .49, 
respectively, for the IMPACT-III subscale, and .69, .85, .48, 
and .51, respectively, for the IBDQ subscale.
Coping was assessed using the Cognitive Emotion Regu-
lation Questionnaire (CERQ). The CERQ contains 36 items, 
scored 1–5, subdivided into nine subscales. These scales 
are divided in two domains: adaptive coping (e.g., positive 
reappraisal) and maladaptive coping (e.g., self-blame and 
catastrophizing). A higher score indicates more use of a par-
ticular coping style (Garnefski, Legerstee, Kraaij, Van Den 
Kommer, & Teerds, 2002). Internal consistency at baseline 
and the three follow-up assessments was .89, .91, .94, and 
.94, respectively, for the adaptive coping domain, and .87, 
.88, .87, and .86, respectively, for the maladaptive coping 
domain.
Illness perceptions were assessed with the Brief Illness 
Perceptions Questionnaire (B-IPQ; Broadbent, Petrie, Main, 
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& Weinman, 2006; De Raaij, Schröder, Maissan, Pool, & 
Wittink, 2012). It contains nine self-report items on cogni-
tive and emotional representations of illness. Eight dimen-
sions (e.g., consequences of illness, personal control, con-
cerns, and understanding) are scored from 0 to 10. A higher 
score represents more negative illness perceptions. Internal 
consistency at baseline and the three follow-up assessments 
was .74, .79, .78, and .75.
Sleep problems were assessed using the sleep problem 
items of the Youth Self-Report (YSR; for ages 10–17; 
Achenbach and Rescorla, 2001) and the Adults Self-Report 
(ASR; for ages 18–25; Achenbach and Rescorla, 2003). 
These questionnaires contain three comparable items on 
sleep problems (scored 0, 1, or 2), of which the scores were 
added up: ‘I sleep more than most other people during day 
and/or night.’ and ‘I have trouble sleeping.’
Clinical disease activity was assessed with four validated 
clinical disease activity measures around the moments that 
the online questionnaires on psychological symptoms were 
filled out. For youth with CD in the age category 10–20, 
the short Pediatric Crohn’s Disease Activity Index (sPC-
DAI; Kappelman et al., 2011) was used; for those with UC 
and IBD-U the Pediatric Ulcerative Colitis Activity Index 
(PUCAI; Turner et al., 2007). For youth with CD in the 
age category 21–25 years, the Crohn’s Disease Activity 
Index (CDAI; Best, Becktel, Singleton, & Kern, 1976) was 
used; for those with UC and IBD-U the partial Mayo score 
(Schroeder, Tremaine, & Ilstrup, 1987). All are physician-
rated forms (not online), which provide four categories of 
clinical disease activity: remission, mild, moderate, and 
severe.
Statistical Analysis
We tested differences in demographic and disease charac-
teristics between the two groups at baseline using t-tests, 
Mann–Whitney tests, and Chi-square tests.
To enable combining data of all participants in one anal-
ysis (thereby maximizing power), despite the use of age-
appropriate instruments, we calculated a Reliable Change 
Index (RCI; Jacobson and Truax, 1991) value separately for 
anxiety and depression (primary outcomes) for each par-
ticipant, at each assessment. The RCI of an instrument is 
calculated from the standard error of measurement (SEM) 
of the pretest reliability and the test–retest reliability. The 
RCI can have three possible values: reliably improved; no 
reliable change; and reliably deteriorated (see Appendix 2 
for RCI details). Chi-square tests were used to test for differ-
ences in RCI values between the two groups. These analyses 
included only youth for whom pre- and posttest data were 
available (see Table 1 for the details on sample sizes for each 
Chi-square test). The proportions of patients who developed 
clinical anxiety and/or depression were compared between 
groups using a separate Chi-square test.
For exploratory analyses, we used linear mixed models 
(taking into account missing data) to compare the change on 
full-range scores from baseline to 6- and 12-month follow-up 
between groups. The outcomes were anxiety (SCARED or 
HADS-A), depression (CDI or BDI-II), HRQOL (IMPACT-
III or IBDQ), social functioning (subscale of IMPACT-III 
or IBDQ), coping (CERQ), illness perceptions (B-IPQ), and 
sleep problems (YSR or ASR). The starting model for all 
outcomes included a random intercept and fixed factors for 
time, group, and the interaction between time and group. 
Next, we examined with the use of likelihood-ratio tests 
whether adding a random slope of time and a quadratic term 
of time and the interaction between the quadratic term of 
time with group improved the model. The restricted maxi-
mum likelihood method was applied, as this is preferred for 
relatively small sample sizes (Luke, 2017; Serrano, 2008). 
Because we had no expectations about the relationship 
between the random intercept and slope, an unstructured 
covariance structure was selected, which is the most flex-
ible structure.
Follow-up data were analyzed based on the intention-
to-treat principle, unless otherwise specified. For the Chi-
square analyses (with the primary dichotomous outcomes), 
this implied inclusion of data of only those randomized for 
whom follow-up data were available (since follow-up data 
were required to calculate the RCI). For the exploratory 
analyses (secondary continuous outcomes), the intention-
to-treat principle implied inclusion of data of all randomized 
participants, also those without follow-up data (since the 
linear mixed models take into account missing data and 
follow-up data were not required). A p value of < .05 was 
considered statistically significant. Data were analyzed using 
SPSS version 24.
Sample Size and Power
Sample size and power were based on anxiety and depres-
sive symptoms as primary outcomes. Meta-analytic studies 
in youth without a somatic disease have shown medium-
to-large effect sizes for anxiety symptoms (Reynolds, Wil-
son, Austin, & Hooper, 2012) and medium effect sizes for 
depressive symptoms (Weisz, McCarty, & Valeri, 2006). 
These correspond with φ > 0.40 and φ > 0.30, for anxiety 
and depressive symptoms, respectively. For the main Chi-
square analyses, this means that a sample size of 70 provides 
enough power for the anxiety outcomes (> 85%, β = 0.14) 
and medium power for the depression outcomes (> 60%, 
β = 0.39).
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Results
Demographic Data
In total, 70 youth were randomized; 37 in the PASCET-PI 
group and 33 in the CAU group (see Fig. 1). Attrition was 
very low; only two patients dropped out of the PASCET-
PI, and only three patients (6 months) and two patients 
(12  months) did not complete follow-up assessments. 
Demographic variables did not significantly differ between 
the groups (see Appendix 3, Table 4): percentage of males 
(27.0% vs. 36.4%, p = .401), mean age (18.62 vs. 17.69, 
p = .393), socioeconomic status (p = .348), and ethnicity 
(p = .749). The numbers of patients included at baseline 
based on anxiety, depression, or both did not differ between 
the groups as well (p = .070). The patients’ disease char-
acteristics did not differ between the groups: IBD subtype 
(% CD 48.6% vs. 54.5%), Paris classification at diagnosis 
(CD location; p = .808, CD behavior; p = .243, UC extent; 
p = .069, UC severity; p = .104), percentage of patients in 
clinical remission (73.0% vs. 78.8%, p = .571), and use of 
IBD medication (% immunomodulators 43.2% vs. 48.5% 
and % biologicals 21.6% vs. 36.4%). However, the median 
disease duration was longer in the PASCET-PI group than 
in the CAU group (2.59 vs. 1.17 years, p = .039). In the 
PASCET-PI group, 18 patients were aged 10–17 years and 
19 patients 18–25 years. In the CAU group, 17 patients were 
aged 10–17 years and 16 patients 18–25 years.
With respect to treatment integrity, adherence to the pro-
tocol was good. The mean number of sessions followed in 
the PASCET-PI group was 9.38 (out of 10). The mean num-
ber of family sessions followed was 2.57 (out of 3), and the 
mean number of booster sessions followed was 2.59 (out of 
3). In all sessions, at least 75% of the topics were discussed.
Effect of Disease‑Specific CBT on Symptoms 
of Depression and Anxiety
In the Chi-square tests, some cells in the crosstabulation 
were smaller than 5. Only few patients (0–4) were in the 
‘Reliable increase of score/deterioration’ category (i.e., dete-
riorated in anxiety or depression). Therefore, we combined 
this category with the ‘No reliable change’ category, to test 
if the PASCET-PI and CAU groups differed with respect to 
the proportions of patients who had improved on anxiety 
or depression. In these main analyses, RCI values for anxi-
ety [χ2 (1) = .226, p = .801] and depression [χ2 (1) = 2.680, 
p = .141] after 6 months did not differ between the groups, 
neither did the RCI values for anxiety [χ2 (1) = .337, p = .626] 
after 12 months. This indicates that in both groups a similar 
proportion of patients had improved. For depression after 
12 months, the RCI values differed significantly between 
the groups, indicating that the proportion of patients in the 
CAU group that had improved was higher than that in the 
PASCET-PI group [χ2 (1) = 5.460, p = .026], see Table 1. In 
the PASCET-PI group, two patients developed clinical anxi-
ety and/or depression during follow-up, versus one patient 
in the CAU group, which was not significantly different [χ2 
(1) = .240, p = .543].
To provide more insight into age differences, we also 
performed the Chi-square analyses separately for the 10- to 
17-year olds and the 18- to 25-year olds. The results almost 
completely matched those from the Chi-square analyses in 
the total group (data not shown). However, the proportion 
of 18- to 25-year olds in the CAU group that had improved 
on depression after 12 months was higher than that in the 
PASCET-PI group [χ2 (1) = 6.349, p = .019].
The exploratory analyses gave similar results as the 
Chi-square analyses. For all outcomes, the residuals of the 
models were approximately normally distributed. For the 
SCARED and the IMPACT-III, the final model included a 
fixed factor for time and group, a random intercept, and a 
random slope for time, since the likelihood-ratio test indi-
cated that adding a random slope for time improved the 
model significantly. Because this was not the case for all 
the other outcomes, the respective models did not include 
a random slope for time. For the BDI-II, the final model 
included fixed factors for time and group, and for the inter-
action between time and group, and a random intercept. 
For all the other outcomes, however, including a fixed 
factor for the interaction between time and group did not 
improve the model. Therefore, for all other outcomes, the 
final model included fixed factors for time and group, and a 
random intercept. For the SCARED, HADS-A, and BDI-II, 
adding a quadratic term of time significantly improved the 
model. Then adding the interaction between the quadratic 
terms of time and group did not improve the model for these 
outcomes.
A significant time–group (PASCET-PI versus CAU 
group) interaction effect was not found for anxiety 
(SCARED: p = .798; HADS-A: p = .997), depression (CDI: 
p = .693), HRQOL (IMPACT-III total score: p = .117; 
IBDQ total score: p = .247), social functioning (IMPACT-
III Social functioning: p = .407; IBDQ Social functioning; 
p = .879), coping (CERQ Adaptive coping: p = .506; CERQ 
Maladaptive coping: p = .592), illness perceptions (B-IPQ: 
p = .474), and sleep problems (YSR/ASR: p = .858). The 
only significant time–group interaction was found on the 
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Fig. 1  CONSORT study flow chart
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BDI-II (p = .025; favoring the CAU group over the course 
of 12 months). Therefore, for all outcomes except the BDI-
II, the effect of time was similar for both groups. Table 2 
presents the coefficients for time presented for the model 
without the interaction of time and group; only for the 
BDI-II the estimate is presented for the model with the 
interaction of time and group included. Cohen’s d reflects 
the effect size for the overall means, since no group differ-
ences were observed, except for the BDI-II. For all out-
comes (except sleep problems; p = .070), the average effect 
of time was significant, indicating that over the course of 
12 months, youth in both groups had improved on their 
psychological outcomes (anxiety, depression, HRQOL, 
social functioning, coping, and illness perceptions). For 
the SCARED, HADS-A, and BDI-II, the quadratic effect 
was significant. This indicates that for these outcomes the 
model follows a quadratic trajectory over the course of 
12 months.
Discussion
In the current RCT, we examined the long-term effects of a 
disease-specific CBT on psychological outcomes of youth 
with IBD. Overall, youth in both groups improved on anxi-
ety and depressive symptoms, HRQOL, social functioning, 
coping, and illness perceptions and these improvements sus-
tained until the final follow-up assessment at 12 months. In 
both groups, a similar proportion of patients improved in 
anxiety and/or depression (main analyses) and the groups 
did not differ in the proportion of patients that developed 
clinical anxiety and/or depression. However, in general, no 
differences between the CBT and CAU groups were found.
Our results are partly in line with the results of similar 
trials. Levy et al. (2016) found that three sessions of SLCBT 
outperformed educational support, but only in improving 
HRQOL (after 1 week of follow-up), coping and school 
attendance (after 12 months of follow-up), and in parent- 
and child-reported distract/ignore coping of the child. In line 
with our results, SLCBT did not have a beneficial effect on 
anxiety, depression, coping, or functional disability. Szigethy 
et al. (2014) found that CBT outperformed supportive non-
directive therapy in improving disease activity after three 
months, with a difference of 10 points in raw disease activ-
ity scores from pre- to post-intervention. When only data of 
patients with active CD were analyzed, CBT was more effec-
tive than was supportive non-directive therapy in improving 
disease activity and somatic depressive symptoms after three 
months of treatment (Szigethy et al., 2015).
Explanations for the lack of an effect of the disease-spe-
cific CBT in our trial may be the following. First, most of the 
participants had no or only mild somatic symptoms at base-
line, reflected by low IBD disease activity scores. Receiving 
the full protocol of CBT may have been “over-treatment” in 
patients with a rather low burden of disease, somatically as 
well as psychologically. Still, many participants remarked 
that the acquired skills would be useful and necessary in 
times of disease exacerbations. Thus, we hypothesize that 
CBT may be more useful for youth with severe anxiety/
depression and/or those with active disease.
Second, participants in the control group may—for the 
very reason that they participated in a trial– have received 
more than just standard medical care. Via the informed 
consent form and the invitation by the medical staff, they 
were informed about psychological problems in IBD. Then, 
they were systematically screened with questionnaires and 
diagnostic interviews. This provided them with the oppor-
tunity to express their emotions and concerns, which may 
have evoked feelings of reassurance and safety. The created 
Table 1  Crosstabulation of 6- and 12-month RCI of symptoms of 
anxiety and depression versus group
a Pearson Chi-square = .226, p = .801, φ = − .058 (95%BI .000–.293). 
Numbers in parentheses indicate row percentages
b Pearson Chi-square = 2.680, p = .141, φ = .200 (95%BI .000–.439). 
Numbers in parentheses indicate row percentages
c Pearson Chi-square = .337, p = .626, φ = .070 (95%BI .000–.306). 
Numbers in parentheses indicate row percentages
d Pearson Chi-square = 5.460, p = .026, φ = .283 (95%BI .036–.521). 
Numbers in parentheses indicate row percentages
Reliable increase of score/
deterioration or no reliable 
change
Reliable decrease of 
score/improvement
Total
6 months
RCI categories anxiety (SCARED or HADS-A)a
 CAU 11 (34.4%) 21 (65.6%) 32
 CBT 14 (40.0%) 21 (60.0%) 35
RCI categories depression (CDI or BDI-II)b
 CAU 11 (34.4%) 21 (65.6%) 32
 CBT 19 (54.3%) 16 (45.7%) 35
12 months
RCI categories anxiety (SCARED or HADS-A)c
 CAU 12 (37.5%) 20 (62.5%) 32
 CBT 16 (44.4%) 20 (55.6%) 36
RCI categories depression (CDI or BDI-II)d
 CAU 8 (25.0%) 24 (75%) 32
 CBT 19 (52.8%) 17 (47.2%) 36
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Table 2  Results of linear mixed models: time effects for outcome variables with overall Estimated Marginal Means
Significant effects are highlighted in bold
NA not applicable
a For the SCARED, HADS-A, CDI, BDI-II, CERQ Adaptive coping, B-IPQ, and YSR/ASR, a negative beta indicates improvement of prob-
Variable β (SE)
(time 
effect)a
p (time 
effect)
β (SE)
(time2 
effect)a
p  (time2 
effect)
Baseline
Mean (SE)
6 Months 
Mean (SE)
Cohen’s d
(base-
line—6 months)
12 Months 
Mean (SE)
Cohen’s d
(base-
line—12 months)
SCAREDb,c
(anxiety; 
10–20 years, 
n = 50)
− 1.065 
(.103)
<.001 .013 (.002) <.001 37.8 (1.9) 18.7 (1.9) − 1.41 18.6 (2.3) − 1.27
HADS-Ac
(anxiety; 
21–25 years, 
n = 20)
− .216 
(.037)
<.001 .003 (.001) <.001 9.5 (0.6) 5.9 (0.6) − 1.39 6.3 (0.6) − 1.14
CDI
(depression; 
10–17 years, 
n = 35)
− .078 
(.013)
<.001 NA NA 9.0 (0.8) 6.9 (0.7) − 0.71 4.9 (0.8) − 1.01
BDI-IIc
(depression; 
18–25 years, 
n = 35)
− .360 
(.057)d
<.001 .005 (.001) <.001 13.9 (1.2) 5.8 (1.1) − 1.82e 5.2 (1.2) − 1.81e
IMPACT-III 
total  scoreb
(HRQOL; 
10–20 years, 
n = 50)
.223 (.035) <.001 NA NA 140.1 (2.0) 146.1 (1.8) 0,82 151.9 (2.1) 0.84
IMPACT-III 
Social func-
tioning
(10–20 years, 
n = 50)
.055 (.013) <.001 NA NA 49.5 (0.8) 51.0 (0.7) 0.47 52.4 (0.8) 0.53
IBDQ total 
score
(HRQOL; 
21–25 years, 
n = 20)
.292 (.094) .003 NA NA 168.1 (3.8) 176.0 (3.1) 1.02 183.5 (4.2) 0.84
IBDQ social 
functioning
(21–25 years, 
n = 20)
.060 (.029) .006 NA NA 29.7 (0.9) 31.3 (0.8) 0.58 32.9 (1.0) 0.71
CERQ adap-
tive coping
(10–25 years, 
n = 70)
− .086 
(.037)
.024 NA NA 59.1 (1.8) 56.8 (1.7) − 0.21 54.6 (2.1) − 0.31
CERQ 
maladaptive 
coping
(10–25 years, 
n = 70)
− .092 
(.020)
<.001 NA NA 27.8 (0.9) 25.3 (0.8) − 0.50 22.9 (1.1) − 0.68
B-IPQ
(illness 
perceptions; 
10–25 years, 
n = 70)
− .149 
(.022)
<.001 NA NA 39.9 (1.3) 35.9 (1.2) 0.55 32.0 (1.4) − 0.71
YSR/ASR
(sleep 
problems; 
10–25 years, 
n = 70)
− .004 
(.003)
.070 NA NA 0.8 (0.1) 0.7 (0.1) 0.24 0.6 (0.1) − 0.26
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awareness may have benefitted all patients, and may have 
been enough to improve subclinical anxiety and depression. 
This also may explain why so few patients in both groups 
developed clinical anxiety and/or depression.
It is unexpected and counterintuitive that at 12 months 
of follow-up the proportion of patients that had improved 
on depressive symptoms was the highest in the CAU 
group, although this only held for the 18- to 25-year olds. 
Youth in this age range have a more advanced cognitive 
development than younger peers. Those receiving CBT 
may find themselves confronted with the life-long impact 
of IBD on, for example, long-lasting romantic relation-
ships, work, and career prospects. This may maintain the 
depressive symptoms. Still, this unexpected finding, may 
have been a chance finding, considering the number of 
statistical tests and also considering that at 3 and 6 months 
no difference in depression was found between the CBT 
and CAU groups.
Furthermore, at baseline, the disease duration in the CBT 
group had been significantly longer than that in the CAU 
group (2.59 vs. 1.17 years). This may have had an effect 
on the outcomes, since a shorter disease duration has been 
associated with lower HRQOL or more emotional/behavio-
ral problems (Hill et al., 2010; Mackner and Crandall, 2005). 
It is not likely, however, that participants in the CBT group 
may have had fewer psychological problems, and, therefore, 
less room to improve considering the fact that both the RCI 
analysis and the exploratory linear mixed models took into 
account the baseline psychological outcomes scores.
Since the PASCET-PI was originally developed and found 
effective for improving mainly depression (Szigethy et al., 
2014), it was unexpected that we found no differences on 
depressive symptoms. Furthermore, we found no additional 
effect on anxiety symptoms, although we adapted the PAS-
CET-PI to also target anxiety. Szigethy et al. (2015) only found 
an additional effect of CBT on somatic depressive symptoms 
and disease activity in patients with active CD. In our study, 
approximately three-quarters of the participants were in clini-
cal remission, which may explain differences in results.
We also did not find differences between the groups in 
improvement in coping and negative illness perceptions. 
Changes in coping or illness perceptions after psychologi-
cal treatment can only be expected if the treatment had 
focused specifically on these factors. The PASCET-PI con-
tains components that may influence coping (e.g., practic-
ing positive thinking) and illness perceptions (e.g., discuss-
ing the illness narrative). Perhaps, the current protocol had 
too little focus on challenging coping styles in the current 
protocol. An alternative explanation may be the low level 
of negative illness perceptions, on account of low disease 
activity (e.g., Schröder et al., 2012; Busscher and Spinhoven, 
2017). However, the secondary analyses were exploratory 
(and conducted in subgroups of patients based on age). As a 
consequence, the study design may not have been the most 
suitable to investigate coping and illness perceptions. Future 
studies should therefore investigate how coping and illness 
perceptions can be the focus of psychological treatment to 
improve anxiety and depression.
Clinical and Future Directions
Considering the results of the current study and that of 
earlier studies into CBT for youth with IBD (Szigethy 
et al., 2014, 2015; Levy et al., 2016), it remains unclear 
which patients with IBD will benefit the most from CBT, 
how the intervention should be delivered, and what out-
comes improve the most.
From our findings we conclude that providing a full 
protocol of disease-specific CBT for preventive purposes 
seems not necessary. We assume that that patients with 
more clinical anxiety and/or depression likely will benefit 
more from CBT, as was found in both youth (Szigethy 
et al., 2014) and adults with IBD (Bennebroek Evertsz 
et al., 2017). Moreover, although this is not clear yet, a full 
protocol of CBT may be more helpful for improving both 
lems and a negative Cohen’s d indicates improvement of problems over time. For the IMPACT-III, IMPACT-III Social functioning, IBDQ, 
IBDQ Social functioning, and CERQ maladaptive coping, a positive beta indicates improvement of problems and a positive Cohen’s d indicates 
improvement of problems over time. For all outcomes, the beta is the time effect for both groups, unless otherwise specified
b For these outcomes, the linear mixed model also included a random slope for time, whereas for all the other outcomes the model included only 
fixed factors and a random intercept
c For these outcomes, the linear mixed model also included a quadratic term of time
d Since the interaction of time and group is significant for the BDI-II, this beta is the time effect for the control group
e For the BDI-II, Cohen’s d reflects the effect size for the control group
Table 2  (continued)
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psychological and somatic symptoms of IBD patients who 
suffer from active disease. However, since these patients 
are often hospitalized or need intensive pharmacologi-
cal treatment, the question arises how the CBT can be 
delivered best to them (e.g., via telephone or Internet). 
Group interventions in the hospital have been shown to 
be promising in youth with IBD (Grootenhuis, Maurice-
Stam, Derkx, & Last, 2009) and effective in youth with 
chronic illnesses (including IBD; Scholten et al., 2013). 
Furthermore, apart from anxiety, depression, and HRQOL, 
other clinically relevant psychological outcomes such as 
social functioning, school attendance, or treatment adher-
ence may be important to target as well. Psychological 
interventions aiming at these outcomes have been shown 
to be effective in youth with either IBD or other chronic 
illnesses (Forgeron, King, Reszel, & Fournier, 2017; Hom-
mel et al., 2012).
Strengths and Limitations
One of the strengths of the current study is the rand-
omized and prospective design, in which the interviewer 
and the treating physicians were blinded to the group 
assignment. In addition, we included patients with a broad 
and clinical relevant age range and our findings have 
external validity since patients came from both rural and 
urban centers (including different therapists). Further-
more, the study had very low attrition and we investigated 
several psychological outcomes. An important limitation 
is that we did not control for attention placebo effects. We 
chose to use standard medical care as control condition, 
because it was already known that CBT as state-of-the-art 
psychotherapy performs better than placebo for anxiety 
and depression. We deemed this the most clinical relevant 
comparison, considering that this best resembles our cur-
rent care. Furthermore, the relatively small sample size 
is a limitation, although the study was sufficiently pow-
ered. In addition, to cover the whole age range, so that the 
exploratory linear mixed models could only be performed 
on subgroups.
Conclusion
Overall, youth in both the CBT and the control group 
improved on their psychological outcomes 6 and 12 months 
after baseline. CBT did not have an additional effect in 
improving anxiety, depression, HRQOL, social functioning, 
coping, illness perceptions, and sleep problems, when com-
pared to the control condition. We think that the awareness 
created by participating in a RCT had a positive effect on the 
psychological outcomes of youth in both groups. Offering a 
full protocol of CBT in youth with relatively low somatic and 
psychological burden does not seem to be necessary.
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Appendix 1
Outline and Tree Diagram of the PASCET‑PI
See Table 3.
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Table 3  Outline of the PASCET-PI (Szigethy et al., 2007; van den Brink et al., 2016)
IBD inflammatory bowel disease, PASCET-PI primary and secondary control enhancement training for physical illness
Session number Content of session
Session 1
Live (60 min)
Introduction of ACT & THINK model and PASCET-PI, building work alliance, psycho-education about IBD and 
depression or anxiety, illness narrative
Session 2
Live (60 min)
Mood monitoring, explaining link between feelings, thoughts, and behaviors, discussing feeling good and feeling bad, 
problem-solving
Session 3
By telephone (30 min)
Link between behavior and feelings: Activities to feel better
Session 4
Live (60 min)
Be Calm and Confident: relaxation exercises
Session 5
Live (60 min)
Be Calm and Confident: positive self versus negative self, training social skills
Session 6
By telephone (30 min)
Talents: developing talents and skills makes you feel better
Session 7
Live (60 min)
Social problem-solving, discussing the ACT skills and introduction of the THINK skills with discussing negative 
thoughts (Think positive/cognitive restructuring)
Session 8
By telephone (30 min)
Help from a friend, Identify the ‘Silver Lining,’ and No replaying bad thoughts
Session 9
By telephone (30 min)
Keep trying—Don’t give up, making several plans to use the ACT & THINK skills
Session 10
Live (60 min)
Quiz on ACT & THINK model, discussing use of ACT & THINK skills in the future, updating illness narrative
Booster 1
By telephone (30 min)
Several plans to use the ACT & THINK skills, updating illness narrative, personalizing ACT & THINK skills
Booster 2
By telephone (30 min)
Several plans to use the ACT & THINK skills, updating illness narrative, personalizing ACT & THINK skills
Booster 3
By telephone (30 min)
Several plans to use the ACT & THINK skills, updating illness narrative, personalizing ACT & THINK skills
Family 1
Live (60 min)
Parental view on IBD, family situation, psycho-education about IBD and depression or anxiety, introduction of ACT & 
THINK model and PASCET-PI
Family 2
Live (60 min)
Parental view on progress, the ACT & THINK skills that are most effective for the patient, expressing emotions within 
family, family communication, family stress game
Family 3
Live (60 min)
Parental view on progress, family communication, parental depression, or anxiety
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Appendix 2
Calculation of Reliable Change Index (RCI) Variables
Step 1 Calculating the standard error of difference for 
each participant, separately for anxiety and depression:
in which x1 and x2 are the individual’s scores on baseline 
and at follow-up, respectively; S1 is the pretest variance 
for that instrument; and rxx is the test–retest reliability of 
the instrument as reported in the manual.
• SCARED (10–20 years): rxx= .81 (Muris et al., 2011) 
| S1 = 13.389→| Sdiff = 8.253
• HADS-A (21–25 years): rxx= .89 (Spinhoven et al., 
1997) | S1 = 2.373→| Sdiff = 1.113
• CDI (10–17 years): rxx= .86 (Timbremont et al., 
2008) | S1 = 4.648→| Sdiff = 2.459
• BDI-II (18–25 years): rxx= .93 (Van der Does, 2002) 
| S1 = 4.381→| Sdiff = 1.639
RC =
x2 − x1
Sdiff
Sdiff =
√
2(SE)2 SE = S1
√
1 − r
xx
,
Step 2 Calculating the difference between the follow-up 
and the baseline for each participant, separately for anxi-
ety and depression.
Step 3 Calculating the RC value for each participant, 
separately for anxiety and depression.
Step 4 Determining the RCI value for each participant, 
separately for anxiety and depression. Both for anxiety 
and depression this leads to a variable with three possi-
ble values: no reliable change, reliable deterioration, and 
reliable improvement. An RC value of between − 1.96 
and 1.96 indicates no reliable change (p < .05). When 
RC is higher than 1.96, this indicates a reliable increase 
in the score (p < .05), i.e., reliable deterioration (as for 
all the instruments applies that a higher score represents 
more symptoms). When RC is lower than − 1.96, this 
indicates a reliable decrease in the score (p < .05), i.e., 
reliable improvement.
Appendix 3
See Table 4.
Tree diagram PASCET-PI
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Table 4  Baseline demographic 
and disease characteristics
PASCET-PI primary and secondary control enhancement training for physical illness, CAU care-as-usual, 
SD standard deviation, IBD inflammatory bowel disease, IBD-U inflammatory bowel disease unclassified, 
SES socioeconomic status
a Chi-square
b ANOVA
c Fisher’s Exact test
d Mann–Whitney test | *UC includes IBD-U patients, †L1: ileocecal, L2: colonic, L3: ileocolonic, L4a: 
upper gastrointestinal tract proximal, and L4b distal from Treitz ligament ‡E1: proctitis, E2: left-sided coli-
tis distal of splenic flexure, E3: extensive colitis distal of hepatic flexure, E4: pancolitis §prednisone (oral 
and intravenous) and budesonide (oral)
PASCET-PI group 
(n = 37)
CAU group (n = 33) p value
Demographic status
 Male, n (%) 10 (27.0) 12 (36.4) .401a
 Age, mean (SD), years 18.62 (4.27) 17.69 (4.82) .393b
SES, n (%)
 Low 8 (21.6) 4 (12.9) .348a
 Middle 15 (40.5) 10 (32.3)
 High 14 (37.8) 17 (54.8)
Ethnicity, n (%) (n = 64)
 Dutch/Western 30 (81.1) 25 (80.6) .749a
 Other 7 (18.9) 6 (19.4)
Included on, n (%)
 Anxiety 30 (81.1) 20 (60.6) .070a
 Depression 0 (0.0) 3 (9.1)
 Both 7 (18.9) 10 (30.3)
IBD subtype, n (%)
 Crohn’s disease 18 (48.6) 18 (54.5) .808a
 Ulcerative colitis 14 (37.8) 12 (36.4)
 IBD-U 5 (13.5) 3 (9.1)
Paris classification at diagnosis, n (%)
 CD: location (n = 36)†
  L1 4 (22.2) 2 (11.1) .813a
  L2 4 (22.2) 4 (22.2)
  L3 6 (33.3) 8 (44.4)
  + L4a/L4b 4 (22.2) 4 (22.2)
 CD: behavior (n = 36)
  Non-stricturing, non-penetrating 18 (100.0) 16 (88.9) .243c
  Stricturing, penetrating, or both 0 (0.0) 2 (11.1)
 UC: extent (n = 34)‡
  Limited: E1 + E2 11 (57.9) 4 (26.7) .069a
  Extensive: E3 + E4 8 (42.1) 11 (73.3)
 UC: severity
  Never severe 18 (94.7) 11 (73.3) .104c
  Ever severe 1 (5.3) 4 (26.7)
Clinical disease activity, n (%)
 Remission 27 (73.0) 26 (78.8) .571a
 Mild 10 (27.0) 7 (21.2)
Disease duration, median, years 2.59 1.17 .039d
IBD Medications, n (%)
 Aminosalicylates 18 (48.6) 12 (36.4) .300a
 Immunomodulators 16 (43.2) 16 (48.5) .660a
 Biologicals 8 (21.6) 12 (36.4) .173a
 Corticosteroids§ 2 (5.4) 5 (15.2) .170c
 Enemas 3 (8.1) 1 (3.0) .352c
 No medication 2 (5.4) 1 (3.0) .543c
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